| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/26/2013 | CN102247404B Pharmaceutical composition for treating lung cancer |
| 06/26/2013 | CN102241751B Novel fungal immunomodulatory protein FIP-NHA with antineoplastic activity and gene thereof |
| 06/26/2013 | CN102188418B Application of salinomycin in preparing medicament for resisting various human malignant tumors |
| 06/26/2013 | CN102153655B Targeted anti-tumor recombinant protein and preparation method thereof |
| 06/26/2013 | CN101918433B Peptides specific for hepatocellular carcinoma cells and applications thereof |
| 06/26/2013 | CN101912400B 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer |
| 06/26/2013 | CN101679256B Mono-hydrochloric salts of an inhibitor of histone deacetylase |
| 06/26/2013 | CN101611058B Prlr-specific antibody and uses thereof |
| 06/26/2013 | CN101505788B Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 06/26/2013 | CN101389338B 双环杂芳基化合物 Bicyclic heteroaryl compound |
| 06/25/2013 | US8471005 Pyrrolotriazines as ALK and JAK2 inhibitors |
| 06/25/2013 | US8470969 Apo-2 ligand/trail formulations |
| 06/25/2013 | US8470850 Inhibitors of VEGF receptor and HGF receptor signalling |
| 06/25/2013 | US8470837 MAPK/ERK kinase inhibitors |
| 06/25/2013 | US8470812 Substituted benzo-pyrimido-tetrazolo-diazepine compounds |
| 06/25/2013 | US8470798 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 06/25/2013 | US8470796 Treatment of cancer by inhibition of IGFBPs and clusterin |
| 06/25/2013 | US8470783 For treating prostate cancer and malignant lymphoma; gene expression inhibition |
| 06/25/2013 | US8470577 Viral vectors and their use in therapeutic methods |
| 06/25/2013 | US8470331 Induce immunology response; antiallergens; bioavailability; autoimmune disease, anticancer agents, antiallergens |
| 06/25/2013 | US8470326 Monoclonal antibody therapy for pancreas cancer |
| 06/25/2013 | US8470317 B7RP-1 antagonists |
| 06/25/2013 | US8470311 Therapeutic agent for anaerobic diseases |
| 06/25/2013 | US8470295 Methods of treatment of androgenic steroidal hormone dependent cancer with auger electron-emitting nucleoside analogs |
| 06/25/2013 | CA2719243C Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same |
| 06/25/2013 | CA2692295C Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer |
| 06/25/2013 | CA2633074C Elongase genes and uses thereof |
| 06/25/2013 | CA2627598C Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| 06/25/2013 | CA2598988C Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing the same as nhe inhibitors |
| 06/25/2013 | CA2595290C Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp |
| 06/25/2013 | CA2591912C Pyrimidinylisoxazole derivatives |
| 06/25/2013 | CA2577446C 2-arylcarbamoyl-indoles as cytokine inhibitors |
| 06/25/2013 | CA2522894C Pharmaceutical composition comprising a bispecific antibody specific for epcam |
| 06/25/2013 | CA2496422C Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
| 06/25/2013 | CA2454578C Modified human thymic stromal lymphopoietin |
| 06/25/2013 | CA2444894C Sustained release drug delivery system containing codrugs |
| 06/25/2013 | CA2380940C Substances and agents for positively influencing collagen |
| 06/25/2013 | CA2328520C Use of anti-prolactin agents to treat proliferative conditions |
| 06/25/2013 | CA2313169C Engraftable neural progenitor and stem cells for brain tumor therapy |
| 06/25/2013 | CA2285241C Substituted 3-cyano quinolines |
| 06/20/2013 | WO2013090836A1 Fluorinated estrogen receptor modulators and uses thereof |
| 06/20/2013 | WO2013090829A1 Estrogen receptor modulators and uses thereof |
| 06/20/2013 | WO2013090732A2 Collateral gene inactivation biomarkers and targets for cancer therapy |
| 06/20/2013 | WO2013090666A1 Compositions containing kinase inhibitors |
| 06/20/2013 | WO2013090645A1 Methods for improving medical therapies |
| 06/20/2013 | WO2013090634A1 Use of polymeric excipients for lyophilization or freezing of particles |
| 06/20/2013 | WO2013090490A1 Tofacitinib salts |
| 06/20/2013 | WO2013090210A1 Metalloenzyme inhibitor compounds |
| 06/20/2013 | WO2013089636A1 Processes for manufacturing of a kinase inhibitor |
| 06/20/2013 | WO2013089252A1 Modification of helper t cell-inducing polypeptide |
| 06/20/2013 | WO2013088853A1 Oligonucleotide, glucocorticoid sensitivity enhancer, drug composition, and expression vector |
| 06/20/2013 | WO2013088400A1 Antiangiogenic brassinosteroid compounds |
| 06/20/2013 | WO2013088338A1 Micrornas and uses therof |
| 06/20/2013 | WO2013088335A1 Crystalline form of cabazitaxel and process for preparing the same |
| 06/20/2013 | WO2013088257A1 Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
| 06/20/2013 | WO2013088256A1 Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors |
| 06/20/2013 | WO2013088250A1 Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| 06/20/2013 | WO2013088141A1 Polypeptide comprising the sequence egpwleeeeeayg linked to an immunogenic carrier |
| 06/20/2013 | WO2013087964A1 Use of agents that alter the peritumoral environment for the treatment of cancer |
| 06/20/2013 | WO2013087920A1 Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
| 06/20/2013 | WO2013087749A1 Potentiation induced by pde4 inhibitors in the treatment of leukemia |
| 06/20/2013 | WO2013087744A1 Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
| 06/20/2013 | WO2013087727A1 New efficient interferon-based treating methods |
| 06/20/2013 | WO2013087647A1 Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer |
| 06/20/2013 | WO2013087643A1 1,3,5 -triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof |
| 06/20/2013 | WO2013087581A1 Amino-substituted imidazopyridazines |
| 06/20/2013 | WO2013087578A1 Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors |
| 06/20/2013 | WO2013087546A1 Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound |
| 06/20/2013 | WO2013087234A1 Nanoparticles and uses thereof |
| 06/20/2013 | WO2013087004A1 Imidazolidinedione compounds and their uses |
| 06/20/2013 | WO2013086804A1 4-pyridyl porphyrin bridged crisscross quad-nuclear platinum complex, and preparation method and anti-tumor activity thereof |
| 06/20/2013 | WO2013086803A1 Trinuclear platinum complex having y-shaped structure and targeting property thereof for human gastric adenocarcinoma cells |
| 06/20/2013 | WO2013086636A1 Soluble igf receptor fc fusion proteins and uses thereof |
| 06/20/2013 | WO2013073968A3 Agents for modulation of cell signalling |
| 06/20/2013 | WO2013063458A3 Inhibiting g protein coupled receptor 6 kinase polypeptides |
| 06/20/2013 | WO2013062365A3 Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy |
| 06/20/2013 | WO2013062349A3 Triticum aestivum lamarck leaf extract or composition containing fractions thereof as active ingredient |
| 06/20/2013 | WO2013058681A3 Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof |
| 06/20/2013 | WO2013052943A3 Small molecule inhibitors of mcl-1 and uses thereof |
| 06/20/2013 | WO2013033268A3 Bivalent bromodomain ligands, and methods of using same |
| 06/20/2013 | US20130158502 Method of inhibiting angiogenesis or invasion or formation of metastases |
| 06/20/2013 | US20130158234 Specific binding agents of human angiopoietin-2 |
| 06/20/2013 | US20130157971 2'-fluoronucleosides |
| 06/20/2013 | US20130157357 Lentiviral vectors for the preparation of immunotherapeutical compositions |
| 06/20/2013 | US20130156721 Cyclodextrin-based polymers for therapeutics delivery |
| 06/20/2013 | US20130156696 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| 06/20/2013 | US20130156695 Use of zcytor17 ligand antagonists for treating inflammatory diseases |
| 06/20/2013 | CA2863557A1 Process of expanding t cells |
| 06/20/2013 | CA2858593A1 Use of polymeric excipients for lyophilization or freezing of particles |
| 06/20/2013 | CA2858389A1 Soluble igf receptor fc fusion proteins and uses thereof |
| 06/20/2013 | CA2858315A1 Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| 06/20/2013 | CA2857749A1 Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
| 06/20/2013 | CA2857337A1 Compositions containing kinase inhibitors |
| 06/20/2013 | CA2857260A1 Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
| 06/20/2013 | CA2857061A1 Novel benzopyran compounds, compositions and uses thereof |
| 06/20/2013 | CA2857057A1 Fluorinated estrogen receptor modulators and uses thereof |
| 06/20/2013 | CA2850706A1 Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound |
| 06/19/2013 | EP2604686A1 Highly functionalized stem cell/progenitor cell by ape1 gene transfection |
| 06/19/2013 | EP2604629A1 Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer |
| 06/19/2013 | EP2604626A1 Fragment of humanized anti-egfr antibody substituted-lysine variable fragment and use thereof |